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Abstract
Background: Testicular germ cell tumors (TGCT) are the most frequent cancers among young men. There is a clear 
familial component to TGCT etiology, but no high-penetrance susceptibility gene has been identified. Epigenetic 
aberrations of the genome represent an alternative mechanism for cancer susceptibility; and, studies suggest that 
epigenetic changes that influence cancer risk can be inherited through the germline. Global DNA hypomethylation has 
been associated with the risk of cancers of the bladder and head/neck.
Methods: We performed a pilot study of global methylation at long interspersed nuclear elements-1 (LINE-1) in 
peripheral blood DNA isolated from 466 family members of 101 multiple-case testicular cancer families.
Results: Investigating the correlation of LINE-1 methylation levels among parent-child pairs independent of affection 
status (n = 355) revealed a strong positive association only between mother-daughter (r = 0.48, P = <0.001) and father-
daughter pairs (r = 0.31, P = 0.02), suggesting gender-specific inheritance of methylation. Incorporating cancer status, 
we observed a strong correlation in LINE-1 methylation levels only among affected father-affected son pairs (r = 0.49, P 
= 0.03). There was a marginally significant inverse association between lower LINE-1 methylation levels and increased 
TGCT risk, compared with healthy male relatives (P = 0.049).
Conclusions: Our data suggest that heritability of LINE-1 methylation may be gender-specific. Further, the strong 
correlation between LINE-1 methylation levels among affected father-affected son pairs suggests that 
transgenerational inheritance of an epigenetic event may be associated with disease risk. Larger studies are needed to 
clarify these preliminary observations.
Background
T esticular germ cell tumors (TGCT) are the most com-
monly diagnosed cancer among young American men
aged 20-35 years, and their incidence has doubled over
the last 40 years [1]. Family history of TGCT is one of the
strongest and most consistent risk factors for this tumor.
Brothers of affected cases have an 8-to 10-fold increased
relative risk compared with the general population and
fathers/sons a 4-and 6-fold higher risk [2,3]. These high
familial risks suggest that inherited susceptibility and/or
environmental factors that cluster in families may
account for a significant portion of TGCT cases. Testicu-
lar microlithiasis (TM), a condition characterized by the
presence of calcium deposits within the seminiferous
tubules, aggregates in families and has been associated
with testicular malignancy [4,5]. Linkage and candidate
gene studies [6-10] have identified several genomic
regions of interest, including Xq27, 2p23, 3p12, 3q26,
12p13-q21 and 18q21-q23. Candidate gene studies have
identified two loci of interest, i.e., the Y-chromosome gr/
gr deletion [9] and the PDE11A gene [8], while recent
GWAS analyses identified KIT-ligand, SPRY4 and BAK1)
[6,7]. However, a specific high-penetrance susceptibility
gene has yet to be proven, suggesting that the combined
contribution of multiple common genetic variants of
lower penetrance may account for the inherited compo-
nent of TGCT susceptibility [10].
Epigenetic changes in the genome, such as aberrant
DNA methylation, are an increasingly recognized con-
tributor to cancer development. TGCTs have distinct
DNA methylation profiles, and parallels have been
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observed between the epigenetic properties of TGCTs
and embryogenesis (e.g., DNA methylation increases with
differentiation) [11]. The seminoma genome is essentially
devoid of DNA methylation, while the nonseminoma
genome is less extensively hypomethylated and has vari-
able CpG island hypermethylation levels [12,13]. A few
tumor suppressor genes are inactivated by DNA pro-
moter hypermethylation in a small proportion of TGCTs,
while DNA hypomethylation of testis-and cancer-associ-
ated genes and unmethylated XIST  are frequently
observed in TGCTs (Reviewed in [11]). Imprinting
defects have also been observed in TGCT somatic tis-
sues, suggesting that epigenetic defects may be present.
In the aggregate, the data suggest that methylation may
provide an alternate genetic mechanism for TGCT sus-
ceptibility.
Transgenerational epigenetic inheritance has been well
studied and documented in many eukaryotic organisms
(e.g., maize, yeast, Drosophila, mice) [14-16], and recent
human studies suggest that epigenetic aberrations that
influence cancer risk can be inherited through the ger-
mline from parent to child [17-20]. Epigenetic patterns
have been observed to segregate in both Mendelian and
non-Mendelian patterns, as well as in a pattern consistent
with environmental exposure. Non-Mendelian and envi-
ronmentally-induced transgenerational inheritance of
epimutations is supported by model organism data [21-
27]. There are several potential modes of transgenera-
tional epigenetic inheritance, including paramutations,
aberrant gene imprinting, and dsRNA processes
(Reviewed in [28]). Retrotransposons are thought to be
resistant to epigenetic reprogramming during embryo-
genesis in mice [29], and thus may play a role in epige-
netic heritability (e.g., if inserted in or near the affected
gene). A recent mouse model study found that transgen-
erational epigenetic inheritance through the germline
controls susceptibility to TGCTs [21].
Global DNA hypomethylation, characterized by a
global loss of 5-methylcytosine (5-mC), contributes to
malignant transformation by activating oncogenes or
latent retrotransposons, such as LINE-1, and by loss of
imprinting [30]. LINE-1 retrotransposons are hypometh-
ylated in many cancers and their lack of repression may
contribute to genome disorganization, expression
changes, and chromosomal instability [31]. The nucle-
otide patterns of LINE-1 repeats have been shown to
both segregate in human pedigrees, and to provide an
individual-specific fingerprint [32]. LINE-1 insertion
dimorphisms may reflect DNA mutations or methylation
changes [32]. Methylation levels at LINE-1 loci have been
shown to differ among different loci in normal tissues,
suggesting that cis-elements near each LINE-1 may influ-
ence their epigenetics [33]. In addition, locus-specific
LINE-1 methylation has been shown to be differentially
influenced by carcinogenic processes, depending on
where the LINE-1s are located in the genome [33]. LINE-
1 retrotransposons are strongly expressed in TGCTs
[31,34,35], and it was hypothesized that active LINE-1
retrotransposon events are involved in primordial germ
cell differentiation, and the consequential genome insta-
bility contributes to malignant transformation [35].
In recent case-control studies, hypomethylation of
peripheral blood DNA was found to be associated with
increased risks of bladder and head/neck cancers, sug-
gesting that global demethylation in genomic DNA is a
potential biomarker of cancer susceptibility [36,37]. We
performed a pilot analysis of global DNA methylation
levels in peripheral blood among family members from
101 multiple-case familiar testicular cancer families.
Methylation at LINE-1 regions using pyrosequencing was
used as a proxy for measuring global methylation levels.
We examined the heritability of the global genomic meth-
ylation phenotype in our families, as well as the associa-
tion between global (LINE-1) methylation levels and
testicular cancer.
Results
DNA from 152 patients with TGCT and 314 unaffected
family members from 101 multiple-case testicular cancer
families were available for LINE-1 methylation analysis.
Table 1 shows the characteristics of the 466 study partici-
pants. Males had significantly higher levels of LINE-1
methylation than females (P = 0.002). There were no sig-
nificant effects of age, smoking, or alcohol consumption
on LINE-1 methylation levels (Additional file 1). There
was no significant difference in mean LINE-1 methyla-
tion between men with and without microlithiasis (P =
0.608).
Inheritance of global (LINE-1) methylation
We assessed whether LINE-1 methylation levels in off-
spring were correlated with either paternal or maternal
levels (n = 355 pairs), irrespective of patient status (Table
2). These analyses revealed a high correlation in LINE-1
methylation between mother-daughter (r  = 0.48, P  =
0.0002; Figure 1) and father-daughter pairs (r = 0.31, P =
0.021), but only a weak correlation between mother-son
(r = 0.18; P = 0.047) and father-son pairs (r = 0.16; P =
0.114).
Figure 1 illustrates LINE-1 methylation level correla-
tions between parent-child pairs after stratifying by tes-
ticular cancer status. There was a statistically significant
correlation in LINE-1 methylation levels between
affected father-affected son pairs (r = 0.49, P = 0.034).
Affected father methylation levels were not significantly
correlated with unaffected son levels (P = 0.228). Further-
more, when comparing unaffected father-and mother-
affected son pairs, no significant associations were dem-Mirabello et al. BMC Medical Genetics 2010, 11:77
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onstrated (r = 0.06, P = 0.738, and r = 0.14, P = 0.257,
respectively). There were no significant differences
between the correlations among unaffected sons and
daughters with affected and unaffected fathers (Figure 1).
Patients with testicular germ cell tumors and global (LINE-
1) methylation
As previously shown, younger age (26-50 years of age)
and the presence of testicular microlithiasis were each
significantly associated with testicular cancer risk (inde-
pendent of methylation levels; Table 3). There was no sta-
tistically significant difference between LINE-1
methylation levels in TGCT patients and healthy male
family members (patient mean: 79.1 [95% CI 78.8-79.5]
versus healthy male mean: = 79.6 [95% CI 79.3-79.9]; P =
0.297). A comparison of LINE-1 methylation as a contin-
uous variable yielded a marginally statistically significant
association between decreasing LINE-1 methylation level
and testicular cancer (OR per unit change = 1.15, 95% CI
1.00-1.32;  P  = 0.049). Males subjects were categorized
into tertiles of LINE-1 methylation level based on the
methylation distribution among healthy male family
members. An upward trend, not statistically significant,
was observed when comparing the lowest and middle ter-
tiles to the highest (OR = 1.41 [95% CI 0.71-2.80] and 1.83
[95% CI 0.91-3.66], respectively; Ptrend = 0.089) (Table 4).
Similarly, with LINE-1 methylation dichotomized at the
median in healthy male controls, lower methylation was
associated with a non-significant increase in testicular
cancer risk (OR = 1.48, 95% CI 0.85-2.55).
Associations between lower LINE-1 methylation and
TGCT risk were stronger in patients with seminoma ver-
sus  non-seminomatous tumors, and in bilateral TGCT
patients versus patients from multi-case families (T able
Table 1: Global (LINE-1) methylation levels and characteristics of all subjects.
Variables No. (%) Mean level* 95% CI P
Family, healthy 255 (54.7) 79.31 79.06-79.56
Family, other cancer 39 (8.4) 79.11 78.47-79.74
Family, other condition§ 20 (4.3) 79.71 78.84-80.58
TGCT patients 152 (32.6) 79.13 78.78-79.45 0.377¶
Multi-case families 118 (77.6) 79.50 79.12-79.88
Sporadic bilateral TGCT 34 (22.4) 78.91 78.21-79.60 0.142¥
Gender‡
Male 114 (44.7) 79.60 79.26-79.95
Female 141 (55.3) 78.87 78.55-79.18 0.002†
Patient TGCT type
NOS 4 (2.6) 77.74 75.68-79.81
Seminoma 73 (48) 79.19 78.70-79.68
Non-seminoma 75 (49.3) 79.59 79.11-80.08 0.267a
Choriocarcinoma 2 (2.7) 79.53 76.86-82.20
Embryonal 15 (20) 79.88 78.90-80.86
Germinoma 2 (2.7) 78.58 75.91-81.26
Mixed germ cell 34 (45.3) 79.19 78.52-79.86
Teratocarcinoma 20 (26.7) 80.78 79.84-81.73
Yolk sac tumor 2 (2.7) 76.06 74.27-79.85
Total participants 466 79.25 79.08-79.43
* Adjusted for age;
§ Other testicular conditions (e.g., hernia or cryptorchidism);
‡ Healthy family only;
¶ For methylation level difference between TGCT patients and healthy family, adjusted for age and sex;
¥ For methylation level difference between patients from multiple case families vs. sporadic bilateral TGCT patients, adjusted for age;
† For methylation level difference between males and females, adjusted for age;
a For methylation level difference between TGCT patients with seminoma vs. non-seminoma, adjusted for age;
NOS = not otherwise specified.Mirabello et al. BMC Medical Genetics 2010, 11:77
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4). We also examined the association between TGCT and
LINE-1 methylation after stratification by age (data not
shown). For those < 50 years, the OR for the lowest LINE-
1 methylation level (1st tertile) was 1.61 (95% CI 0.57-
2.59), versus 1.48 (95% CI 0.48-4.60) for those ≥50.
Discussion
We found that males had significantly higher global
(LINE-1) methylation levels than females, consistent with
prior reports [37-39]. This difference has been variably
attributed to gender-related dietary differences, reduced
circulating levels of folate due to female menstruation,
and/or the presence of an additional X chromosome in
female cells [37,39]. We found no association between
LINE-1 methylation levels and age [36,37,40], smoking
[36,38], or alcohol usage [36,37], also consistent with
prior studies.
LINE-1 methylation levels of offspring were found to be
significantly positively correlated with parental levels,
particularly between mother-daughter, father-daughter,
and affected father-affected son pairs. There are limited
data investigating epigenetic inheritance in humans,
although it has been suggested that epimutations may be
maintained more frequently during oogenesis [41,42]
than during spermatogenesis [43]. Differences in epige-
netic reprogramming between maternal and paternal
genomes have been observed in mouse and drosophila
studies [22,23,25-27]. In mice, epigenetic inheritance at a
locus involved in fur color demonstrated that there was
incomplete erasure of an epigenetic modification at a ret-
rotransposon when passed through the female germ line
[23].
However, others have shown that exposure to an endo-
crine disruptor during embryonic gonadal sex determina-
tion in rats induced permanent DNA methylation
imprinting of the male germline (i.e., sperm) that was
transmitted to subsequent generations [25-27]. This epi-
genetic alteration was associated with transgenerational
disease states (approximately 85% frequency), including
abnormalities in testis function, male infertility, and
tumor development. This observation illustrates how an
environmental exposure can epigenetically reprogram
the germline and promote adult-onset defects in the ger-
mline, providing one possible mechanism by which envi-
ronmental exposures may promote TGCTs [44].
Transgenerational epigenetic interactions have been
shown to control susceptibility to TGCTs in mice with
Dead-end homologue 1 (Dnd1) mutations [21]. It was
suggested that these epigenetic modifiers may mark the
germline, and offspring that also carry a genetic suscepti-
bility factor will have an increased risk of TGCTs; or,
environmental factors may influence genes to act as
mediators and to monitor cellular conditions that then
induce epigenetic alterations [28]. Lam et al. [21] sug-
gested that, in humans, transgenerational epigenetics
may explain the 2-3 fold risk difference in brothers and
sons of TGCT affected individuals. The strong correla-
tion we observed between LINE-1 methylation levels
among affected father-affected son pairs may reflect an
inherited or germline LINE-1 hypomethylation abnor-
mality. Such an inherited epigenetic event could be asso-
ciated either with an environmental factor or genetic
susceptibility.
We observed an association between TGCT and global
hypomethylation that was marginally significant when
considering LINE-1 methylation as a continuous variable
after controlling for potential confounders and testicular
cancer risk factors (age and microlithiasis). Our study had
≥80% statistical power to detect ORs of 1.6 and 2.4 with
LINE-1 methylation in the second and first tertiles,
respectively, assuming a type I error of 0.05. Other stud-
ies have found that global hypomethylation in DNA from
blood was associated with bladder and head/neck cancers
[36,37]. Genomic global (LINE-1) methylation may be an
independent risk factor or a phenotypic marker of cancer
risk associated with genetic instability, aberrant epige-
netic regulation, or other factors.
Our small sample size with attendant reduced statisti-
cal power to detect differences in LINE-1 methylation
levels is a limitation of this study , although ours is the
Table 2: Intra-familial correlations adjusted for age.
Relationship No. of pairs r† P value
Parent-children 355 0.228 <0.0001
Mother-children 190 0.271 0.0002
Mother-daughter 59 0.476 0.0002
Mother-son 131 0.176 0.047
Father-children 165 0.187 0.018
Father-daughter 58 0.308 0.022
Father-son 107 0.157 0.114
†Spearman rank correlation coefficient adjusted for parental age, offspring age, and disease status of the males.Mirabello et al. BMC Medical Genetics 2010, 11:77
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largest cohort of multiple-case families available for anal-
yses of this kind. The family-based design of this study
also limits our exploring the association between TGCT
and global hypomethylation levels, since we have
observed that this may be an heritable phenotype; a non-
family based matched control group would be a useful
follow-up. However, the unique multiple-case family
design of this study is a strength for investigating inheri-
tance, which allowed us to study multiple individuals per
family with and without cancer, and to eliminate potential
confounding due to ethnic background or population
stratification.
LINE-1 retrotransposons are highly-activated in
TGCTs and may lead to insertional mutations, transcrip-
tional deregulation, DNA breaks, and an increased fre-
quency of recombinational events [31,34,35]. Little is
known regarding the mechanisms underlying hypometh-
ylation changes of LINE-1 sequences; however, available
data suggest that LINE-1 retrotransposon events may
contribute to genome instability and malignant transfor-
Figure 1 Familial relations of global (LINE-1) methylation levels by patient status. Each plot shows the number of pairs (n), correlation coeffi-
cient (r) and corresponding P value. Affected refers to patients with cancer, and unaffecteds are cancer-free.Mirabello et al. BMC Medical Genetics 2010, 11:77
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mation. This is the first study to show that global LINE-1
methylation levels may be inherited from parent to child
in humans, and that hypomethylation is associated with
testicular cancer risk. More research is needed to help
explain differences in maternal/paternal effects and
mechanisms of transgenerational epigenetic inheritance.
Conclusions
The results of this study suggest that LINE-1 methylation
is heritable in humans, and that transgenerational inheri-
tance of LINE-1 methylation levels may be associated
with testicular cancer risk. The incomplete penetrance
and non-Mendelian inheritance of epigenetic variation
are consistent with complex disease phenotypes, which
familial testicular cancer displays, and thus it may provide
some insight into the basis of this complex disease. It has
proved difficult to identify high-penetrance TGCT sus-
ceptibility genes in humans, despite a high familial risk
and likely inherited susceptibility. Transgenerational epi-
genetic mechanisms could help explain the difficulty of
finding classical TGCT susceptibility genes in humans.
Larger studies are warranted to further explore the asso-
ciation between genomic global hypomethylation and
TGCT risk, and to investigate the hypothesis that LINE-1
epigenetic inheritance is associated with TGCT suscepti-
bility.
Methods
Study population
Families with two or more cases of TGCT or a single fam-
ily member with bilateral testicular cancer were ascer-
tained as part of the NCI Clinical Genetics Branch
Familial TGCT study, details of which are described else-
where [4]. Men with sporadic bilateral TGCT were
included because of the known excess risk of bilateral
affection in familial TGCT [45]. In brief, "cases" were
men with histologically-confirmed cancer of one or both
testes. Family members were invited to participate in the
study if they were first -degree relatives of a case (aged
≥12yrs), spouses of a case who had participating children,
non-first-degree blood relatives who provided a genetic
link between cases, or blood relatives with cancer. All
participants completed detailed questionnaires of medi-
cal and family history and risk factors, provided blood
samples, and a subset of participants underwent a
detailed medical evaluation at the NIH Clinical Center.
Blood was collected between 2003 and 2006 and stored at
the NCI/CGB Biorepository. The majority of patients
underwent blood collection 5 or more years after they
were diagnosed with TGCT (mean time between diagno-
sis and blood draw was 9 yrs; median time = 5 yrs). We
observed no significant correlation between number of
years from cancer diagnosis/treatment to study blood
Table 3: Association of individual variables with patient status.
Variables Healthy Males TGCT Cases OR† (95% CI)
No. (%) No. (%)
Age:
0-25 27 (23.68) 11 (7.28) 1.00 (ref)
26-50 34 (29.82) 108 (71.52) 8.30 (3.62, 19.05)
51-75 47 (41.23) 31 (20.53) 1.72 (0.72, 4.10)
76-100 6 (5.26) 1 (0.66) 0.52 (0.05, 4.92)
Alcohol use:
Never 25 (30.86) 39 (26.90) 1.00 (ref)
Former 14 (17.28) 33 (22.76) 1.12 (0.45, 2.77)
Current 42 (51.85) 73 (50.34) 0.78 (0.38, 1.64)
Smoking status:
Never 41 (50.00) 97 (66.44) 1.00 (ref)
Former 28 (34.15) 38 (26.03) 0.67 (0.33, 1.35)
Current 13 (15.85) 11 (7.53) 0.42 (0.16, 1.14)
Microlithiasis
No 23 (88.46) 32 (59.26) 1.00 (ref)
Yes 3 (11.54) 22 (40.74) 5.69 (1.41, 23.04)
† Odds ratios (95% confidence intervals) adjusted for age and/or microlithiasis status.Mirabello et al. BMC Medical Genetics 2010, 11:77
http://www.biomedcentral.com/1471-2350/11/77
Page 7 of 9
draw and methylation level (P = 0.492; data not shown).
The parent study has been reviewed and approved by the
NCI Institutional Review Board (NCI Protocol 02-C-
0178; NCT00039598), and all participants provided writ-
ten informed consent.
DNA extraction and bisulfite treatment
Genomic DNA was extracted from fresh whole blood by
standard methods. For bisulfite conversion, DNA was
treated using EZ DNA Methylation-Gold™ Kit (Zymo
Research Corp., CA, USA) according to the manufac-
turer's recommendations. The final elution was per-
formed with 30 μl of M-Elution Buffer.
LINE-1 PCR and pyrosequencing
DNA methylation (%5-mC) of LINE-1 was quantified
using PCR-pyrosequencing of the bisulfite-treated DNA
by EpigenDx Laboratory Service (Worcester, MA), as pre-
viously described [46]. In brief, the bisulfite-treated DNA
was amplified by PCR using primers designed toward a
consensus LINE-1 sequence. A 50-μL PCR was carried
out in 25-μL GoTaq Green Master mix (Promega, Madi-
son, WI, USA), 1 pmol of the forward primer (TTTT-
GAGTTAGGTGTGGGATATA), 1 pmol of the
biotinylated reverse primer (biotin-AAAATCAAAAAA
TTCCCTTTC), 50 ng of bisulfite-treated genomic DNA,
and water. Biotin-labeled primers were used to purify the
final PCR product using Sepharose beads. The PCR
product was bound to Streptavidin Sepharose HP (Amer-
sham Biosciences, Uppsala, Sweden) and the Sepharose
beads containing the immobilized PCR product were
purified, washed, and denatured using a 0.2 M NaOH,
and washed again using the Pyrosequencing Vacuum
Prep Tool (Pyrosequencing, Inc., Westborough, MA,
USA), as recommended by the manufacturer. Then, 0.3
μM of the pyrosequencing primer was annealed to the
purified single-stranded PCR product and pyrosequenc-
ing was performed using the PSQ-HS 96 Pyrosequencing
Table 4: Association of TGCT with blood-derived DNA global (LINE-1) methylation levels.
Relative methylation 
level in tertiles
Healthy Males§ TGCT Cases* OR† (95% CI) P value
No. (%) No. (%)
All patients
Low (≤78.8) 38 (33.3) 57 (37.8) 1.83 (0.91, 3.66) 0.089
Middle (78.9-80.6) 39 (34.2) 52 (34.4) 1.41 (0.71, 2.80)
High (>80.6) 37 (32.5) 42 (27.8) 1.00 (ref)
Patients with seminoma
Low 38 (33.3) 29 (39.7) 2.21 (0.90, 5.43) 0.085
Middle 39 (34.2) 27 (37.0) 1.76 (0.72, 4.30)
High 37 (32.5) 17 (23.3) 1.00 (ref)
Patients with non-seminoma
Low 38 (33.3) 26 (35.1) 1.56 (0.67, 3.66) 0.306
Middle 39 (34.2) 23 (31.5) 1.18 (0.50, 2.78)
High 37 (32.5) 25 (33.8) 1.00 (ref)
Multi-case families‡
Low 38 (33.3) 41 (35.3) 1.68 (0.80, 3.49) 0.174
Middle 39 (34.2) 41 (35.3) 1.51 (0.74, 3.10)
High 37 (32.5) 34 (29.3) 1.00 (ref)
Bilateral TGCT families¶
Low 38 (33.3) 15 (44.1) 2.12 (0.75, 6.01) 0.218
Middle 39 (34.2) 11 (32.4) 1.23 (0.43, 3.46)
High 37 (32.5) 8 (23.4) 1.00 (ref)
† Odds ratios (95% confidence intervals) adjusted for age and microlithiasis status;
§ Males without cancer or other testicular abnormalities;
* Only 151 total TGCT cases, one subject with teratocarcinoma failed bisulfite conversion;
‡ Families with two or more cases of TGCT;
¶ A single family member had bilateral testicular cancer.Mirabello et al. BMC Medical Genetics 2010, 11:77
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System (Pyrosequencing, Inc.). The relative 5-mC con-
tent was expressed as percentage of methylated cytosines
divided by the sum of methylated and unmethylated cyto-
sines (5-mC/[5-mC + unmethylated cytosine] = %5-mC).
Built-in controls were used to verify bisulphite conver-
sion efficiency . T o increase precision, each sample was
tested four times for LINE-1 methylation, and the 4-test
mean was used in statistical analyses. The coefficient of
variation (CV) among 48 blinded replicate samples was
5.7%, and the inter-plate CV was 2.9%.
Statistical analysis
We tested the intra-familial (parent-offspring pairs) cor-
relation of LINE-1 methylation using Spearman rank cor-
relations. Scatterplots were also used to explore the
relationship between LINE-1 methylation levels and par-
ent-child pairs. In this analysis, male participants were
stratified according to their testicular cancer status.
These correlations were adjusted for parental and off-
spring age, and the un-stratified analyses were addition-
ally adjusted for case status. Spearman rank correlations
and general linear models were used to investigate the
strength of the associations between %5-mC and age,
smoking status (never, current, former), and alcohol con-
sumption (never, current, former). We adjusted for age in
all analyses, since age has been associated with global
hypomethylation [47,48]. For microlithiasis, only men
who have had a testicular ultrasound were included in the
analysis as lacking microlithiasis. We used linear regres-
sion models to evaluate potential predictors of LINE-1
methylation levels, as a continuous variable. To evaluate
the association between TGCT and LINE-1 methylation,
we used unconditional logistic regression models to cal-
culate the odds ratio (OR) and 95% confidence intervals
(CI) adjusting for potential confounders (e.g., age). LINE-
1 methylation levels were categorized in tertiles and
dichotomized at the median, based on the distribution in
the healthy male family controls; females were excluded
from these analyses. We computed the variance of the OR
estimates using a robust variance estimator [49] to adjust
for the correlations between participants from the same
family. Covariate data were taken from study question-
naires, physician history and physical exams. All tests
were two-sided. Statistical significance refers to a P ≤ 0.05
or an OR 95% CI that excludes 1.0. All analyses were car-
ried out using SAS software version 9.1 (SAS Institute,
Cary, NC).
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